((自动化翻译由路透提供，请见免责声明 )) (在第 3 段中增加试验细节，在第 2 段中增加股份)
路透10月16日 - 美国食品和药物管理局周三表示，出于安全考虑，Novavax公司的 COVID和流感联合疫苗以及独立流感疫苗的试验被暂停。
这家疫苗生产商的股票在盘前交易中下跌约27%，至9.20美元。
该公司称，一名在中期试验中接种了复合疫苗的受试者报告称运动神经受损，因此暂缓接种。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.